America: beware of Asia double edged sword
American drug manufacturers are playing with a double-edged sword in Asia, warns a recent report.
American drug manufacturers are playing with a double-edged sword in Asia, warns a recent report.
Swiss-based Novartis has acquired a 25 per cent stake in Alcon, a US-based company specializing in ophthalmics, which ranks among the fastest-growing therapeutic sectors in pharmaceuticals.
India's Jubilant Organosys has made good on promises to make acquisitions in the contract research and manufacturing services (CRAMS) sector with a $255m deal to buy Draxis Health of Canada.
IT services firm Court Square used the Interphex trade show in Philadelphia to unveil its new audit and compliance offering for life science firms.
Genzyme is putting another €130m into its manufacturing facility in Waterford, Ireland, where the US biotech first put down roots in 2001 and has been steadily expanding ever since.